In states where recreational cannabis products are still illegal, authorities are seeing a large increase in sales of products containing delta-8-THC. “Delta-8” is a chemical cousin of delta-9-THC, the main cannabinoid responsible for the euphoria of marijuana. Delta-8 is less potent than delta-9, but interacts with the same brain receptors and can produce a “high.” Unfortunately, delta-8 interferes with testing for delta-9 in both presumptive and definitive urine drug tests, according to Quest Diagnostics Medical Science Liaison, Jack Kain, PharmD.
Use of so-called “full-spectrum” formulations of cannabidiol (CBD) products can cause users to test positive for THC, the component of marijuana that causes euphoria, according to an open-label study published in JAMA Psychiatry.
Clinical drug testing fell by over 50% in spring of 2020 due to the COVID-19 pandemic, according to a new study from Quest Diagnostics®. At the same time, the proportion of samples testing positive for dangerous illicit drugs and drug combinations rose.
In mandated tests of employees in safety-sensitive jobs, marijuana had the highest rate of drug positivity, followed by opioids and amphetamines, according to the 2020 Quest Diagnostics Drug Testing Index™ report. The report includes data from over 2.4 million tests from January to December 2019 of workers in safety-sensitive positions undergoing federally mandated drug tests. These include workers in the airline, transportation, and marine industries, among others.
The rate of drug test positivity in the workforce hit a 16-year high in 2019, according to data from the annual Quest Diagnostics Drug Testing Index™ report. Data for the report are drawn from nearly 9 million urine drug tests performed during the year by Quest, the world’s leading provider of diagnostic information services. Overall, 4.5% of samples tested indicated use of an illicit drug.
New options for Specimen Collection from Quest Diagnostics Drug Monitoring. Clinical Drug Monitoring is a critical tool to measure and assess prescription compliance and help identify drug misuse. With the ongoing COVID-19 pandemic and social distancing, many patients are not getting to their physicians’ offices for the drug monitoring testing they need.
New Case Study now available: When considering Opioid therapy—the importance of baseline drug testing for amphetamines and methamphetamines. When following CDC guidelines and ordering baseline drug testing prior to initiating opioid therapy, it can be challenging to identify potential amphetamine and methamphetamine misuse. This case study illustrates some steps that could be appropriate to take to better understand your patient’s potential use or misuse of these two drugs.
Pill shaving refers to the practice of scraping or crushing part of a pill to dissolve it in a urine sample. What can you do to rule out pill shaving?
Presumptive drug testing can give you rapid results that can be used to help improve patient care. But whether a presumptive test is right for your patient depends on many factors, according to Dr. Leland McClure, Director, Medical Science Liaison, Medical Affairs at Quest Diagnostics, and understanding the complexities of presumptive testing is vital for making the right testing choice. Dr. McClure outlined these complexities in a recent webinar.
Opioids and other medications (non-opioid analgesics, benzodiazepines, antidepressants, anticonvulsants, muscle relaxants) are prescribed to treat chronic pain of non-cancer origin. Ongoing monitoring of these patients is important to ensure safe and effective therapy.